Cullinan Therapeutics Faces 52-Week Low Amid Investor Concerns Cullinan Therapeutics has hit a 52-week low, trading at $8.35, reflecting a 53.77% drop over the past year. Despite this, the company maintains strong liquidity with no debt and a current ratio of 13.5. Analysts maintain optimism, with price targets ranging from $29 to $38, highlighting potential recovery opportunities.123